Articles from Minze Health

Minze Health, a digital health company, today announced a three-year agreement with Medtronic, a global leader in healthcare technology, to commercialize the Minze Diary Pod across the EMEA region. The agreement will expand the support services available for patients with bladder control symptoms, known as Overactive Bladder (OAB), undergoing Sacral Neuromodulation (SNM) therapy with a Medtronic InterStim™ system.

Minze Health, a leader in digital diagnostics and therapeutics for urology, and Apogepha Arzneimittel GmbH (“Apogepha”), a family-owned specialty pharmaceutical company focused on urology, today announced a joint development agreement to co-develop and commercialize a prescription digital therapeutic (DTx) for men suffering from Lower Urinary Tract Symptoms (LUTS).

Minze Health, a leader in digital diagnostics and therapeutics for urology, announced today that Thomas Moore has been appointed President and Chief Executive Officer, effective immediately. Moore brings over two decades of commercial leadership in medtech and a proven track record of driving growth, reimbursement, and global market expansion across the U.S. and Europe.

Minze Health, a pioneer in digital health solutions for urology, has successfully secured USD 5.3 million in a funding round led by its existing investors White Fund, Capricorn Digital Growth Fund, and the Flemish investment company PMV. The funding round also saw the participation of a new investor, imec.istart future fund, marking a significant step forward for the company’s growth and innovation.

Minze Health announced today that White Fund, Capricorn Partners and PMV have jointly invested €3.9 million in the company to fund its further growth and product development roadmap.